

Colorectal Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

<https://marketpublishers.com/r/C5C7D5EB705EN.html>

Date: June 2018

Pages: 99

Price: US\$ 5,950.00 (Single User License)

ID: C5C7D5EB705EN

Abstracts

This report can be delivered to the clients within 48 Hours

The global colorectal cancer (CRC) drugs market size is expected to reach USD 10.8 billion by 2022, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 3.3% during the forecast period. Several factors such as increasing target population and rising adoption of targeted therapies are anticipated to fuel market growth.

Products in the pipeline are striving to meet some of the unmet needs of the colorectal cancer (CRC) market. If approved, Array Biopharma's cetuximab plus encorafenib would become the first therapy indicated for BRAF-mutant mCRC treatment. Sumitomo Dainippon's Napabucasin is a cancer stem cell inhibitor targeting STAT-3.

There are few available adjuvant/neoadjuvant medicines for treatment of high-risk resectable colorectal cancer. Lack of pipeline agents in this setting presents a good opportunity for development of effective treatments that can improve cure rates for resected patients. At present, most available treatments for resectable CRC include cheaper chemotherapeutic regimens and generics.

Upcoming patent expiries of key products such as Roche's Avastin, Amgen's Vectibix, and Sanofi's Zaltrap will lead to biosimilar penetration. Amgen/Allergan's Mvasi marked the first Avastin biosimilar approval in U.S. and Europe in 2017 and 2018,

respectively. Cizumab and Krabeva are some of the biosimilars to Avastin launched in India. Several other biosimilars to Avastin and Erbitux are under development.

Further key findings from the report suggest:

Immunotherapy dominated the market based on drug class in 2016, owing to increasing adoption of targeted therapies such as Avastin and Erbitux

Chemotherapy is likely to lose market share on account of non-specificity, adverse effects, and development of resistance to chemical agents. However, recent launch of anti-PD1 drugs such as Opdivo and Keytruda is likely to change the current landscape due to their target-oriented mechanism of action

U.S. accounted for the largest share based on country and is projected to maintain its dominance through to 2022 owing to growing disease burden, increasing treatment rate, and high cost of drugs

Roche led the colorectal cancer industrial setting in 2016 due to growing usage of Avastin. Avastin was the highest revenue-generating CRC medicine in 2016. However, Roche is projected to lose market share on grounds of Avastin's patent expiry and biosimilar penetration

Bristol-Myer Squibb and Merck are anticipated to be market leaders in the colorectal cancer drugs market space by 2022 due to increasing adoption of targeted therapies such as Opdivo and Keytruda.

Contents

CHAPTER 1 RESEARCH METHODOLOGY

- 1.1 Information Procurement
- 1.2 Information or Data Analysis
 - 1.2.1 Market formulation & validation

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY

- 3.1 Disease Primer
 - 3.1.1 Stages:
 - 3.1.2 Symptoms
 - 3.1.3 Risk Factors
- 3.2 Epidemiology by Indications
- 3.3 Current Prevalence for Seven Major Markets (U.S., Japan, EU5)
- 3.4 Current Incidence for Seven Major Markets (U.S., Japan, EU5)
- 3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)

CHAPTER 4 GLOBAL COLORECTAL CANCER DRUGS MARKET OVERVIEW

- 4.1 Introduction and Market Overview
 - 4.1.1 Segmentation, by Drug Class
 - 4.1.1.1 Chemotherapy
 - 4.1.1.1.1 Antimetabolites
 - 4.1.1.1.2 Alkylating agents
 - 4.1.1.2 Immunotherapy
 - 4.1.1.2.1 Biologic Response Modifiers
 - 4.1.1.2.2 Colony-Stimulating Factors
 - 4.1.1.2.3 Tumor Vaccines
 - 4.1.1.2.4 Monoclonal Antibodies
 - 4.1.2 Segmentation, by Region
 - 4.1.2.1 U.S.
 - 4.1.2.2 U.K.
 - 4.1.2.3 Germany
 - 4.1.2.4 Spain
 - 4.1.2.5 Italy

- 4.1.2.6 France
- 4.1.2.7 Japan
- 4.1.3 Market size and forecast
- 4.1.4 Sales performance
- 4.1.5 Market share distribution
- 4.1.6 Market dynamics among leading brands
- 4.2 Patent Expiry Schedule
- 4.3 Drivers and Challenges
- 4.4 M&A, Deal Landscape (YTD 2013-2018)
- 4.5 Pricing and Reimbursement
- 4.6 Emerging Markets
 - 4.6.1 India
 - 4.6.2 China
 - 4.6.3 South Korea
- 4.7 SWOT Analysis

CHAPTER 5 COLORECTAL CANCER DRUGS MARKET: PIPELINE INTELLIGENCE

- 5.1 Pipeline Landscape
 - 5.1.1 Drugs in development
 - 5.1.2 Key R&D trends
 - 5.1.2.1 Molecular targeted therapy
 - 5.1.2.2 Immunotherapy
 - 5.1.2.3 Biosimilars
- 5.2 Promising Drugs
 - 5.2.1 Late-stage pipeline
 - 5.2.2 Profile of disruptive drugs
 - 5.2.2.1 Tecentriq
 - 5.2.2.2 Binimetinib+Encorafenib+Cetuximab
 - 5.2.2.3 MK-3475-177
 - 5.2.2.4 Napabucasin

CHAPTER 6 COMPANY PROFILES

- 6.1 Amgen
 - 6.1.1 Company overview
 - 6.1.2 Current product portfolio
 - 6.1.3 Product forecast sales up to 2022
 - 6.1.4 Company - Key news flow

- 6.1.5 Pipeline view
- 6.1.6 Pipeline forecast
- 6.1.7 Catalysts and event calendar
- 6.1.8 SWOT analysis
- 6.2 Bayer
 - 6.2.1 Company overview
 - 6.2.2 Current product portfolio
 - 6.2.3 Product forecast sales up to 2022
 - 6.2.4 Company - Key news flow
 - 6.2.5 Pipeline view
 - 6.2.6 Pipeline forecast
 - 6.2.7 Catalysts and event calendar
 - 6.2.8 SWOT analysis
- 6.3 Bristol-Myers Squibb
 - 6.3.1 Company overview
 - 6.3.2 Current product portfolio
 - 6.3.3 Product forecast sales up to 2022
 - 6.3.4 Company - Key news flow
 - 6.3.5 Pipeline view
 - 6.3.6 Pipeline forecast
 - 6.3.7 Catalysts and event calendar
 - 6.3.8 SWOT analysis
- 6.4 Eli Lilly
 - 6.4.1 Company overview
 - 6.4.2 Current product portfolio
 - 6.4.3 Product forecast sales up to 2022
 - 6.4.4 Company - Key news flow
 - 6.4.5 Catalysts and event calendar
 - 6.4.6 SWOT analysis
- 6.5 Merck
 - 6.5.1 Company overview
 - 6.5.2 Current product portfolio
 - 6.5.3 Product forecast sales up to 2022
 - 6.5.4 Company - Key news flow
 - 6.5.5 Pipeline view
 - 6.5.6 Pipeline forecast
 - 6.5.7 Catalysts and event calendar
 - 6.5.8 SWOT analysis
- 6.6 Roche

- 6.6.1 Company overview
- 6.6.2 Current product portfolio
- 6.6.3 Product forecast sales up to 2022
- 6.6.4 Company - Key news flow
- 6.6.5 Pipeline view
- 6.6.6 Pipeline forecast
- 6.6.7 Catalysts and event calendar
- 6.6.8 SWOT analysis
- 6.7 Sanofi
 - 6.7.1 Company overview
 - 6.7.2 Current product portfolio
 - 6.7.3 Product forecast sales up to 2022
 - 6.7.4 Company - Key news flow
 - 6.7.5 SWOT analysis

CHAPTER 7 MARKET OUTLOOK

- 7.1 What the Future Holds
- 7.2 Winners and Losers
- 7.3 Emerging Companies
- 7.4 The Road Ahead

List Of Tables

LIST OF TABLES

- Table 1 Current Colorectal Cancer Prevalence Across Seven Major Markets - 2016
- Table 2 Current Colorectal Cancer Incidence Across Seven Major Markets - 2016
- Table 3 Forecast Colorectal Cancer Prevalence across Seven Major Markets, 2016 - 2022
- Table 4 Forecast Colorectal Cancer Incidence across Seven Major Markets, 2016 - 2022
- Table 5 Colorectal Cancer Drugs Market Size and Forecast (in \$million)
- Table 6 Geographic Sales Performance by Seven Major Markets (in \$million)
- Table 7 Colorectal Cancer Drugs Market by Drug Class (in \$million)
- Table 8 Forecast Sales of Leading Brands (in \$million)
- Table 9 Global Colorectal Cancer Drugs Pipeline Forecast
- Table 10 Global Colorectal Cancer Drugs Pipeline Sales Forecast (in \$million)
- Table 11 Colorectal Cancer Drugs Sales Forecast by Company (in \$million)
- Table 12 Colorectal Cancer Drugs Market Share by Company (in \$million)
- Table 13 Colorectal Cancer Drugs Market: Patent Expiry Schedule
- Table 14 Colorectal Cancer Deal Landscape YTD (2013 - 2018)
- Table 15 Colorectal Cancer Drugs in Development
- Table 16 Late-Stage Colorectal Cancer Pipeline
- Table 17 Profile of Disruptive Drug: Tecentriq
- Table 18 Profile of Disruptive Drug: Binimetinib+Encorafenib+Cetuximab
- Table 19 Profile of Disruptive Drug: MK-3475-177
- Table 20 Profile of Disruptive Drug: Napabucasin
- Table 21 Product Portfolio: Vectibix
- Table 22 Product Portfolio: Mvasi
- Table 23 Vectibix Sales Forecast Through 2022
- Table 24 Mvasi Sales Forecast Through 2022
- Table 25 Amgen Pipeline View
- Table 26 Amgen Catalysts and Event Calendar
- Table 27 Product Portfolio: Stivarga
- Table 28 Stivarga Sales Forecast Through 2022
- Table 29 Bayer Pipeline View
- Table 30 Bayer Catalysts and Event Calendar
- Table 31 Product Portfolio: Opdivo
- Table 32 Opdivo Sales Forecast Through 2022
- Table 33 Bristol Myers Squibb Pipeline View

Table 34 Bristol Myers Squibb Catalysts and Event Calendar

Table 35 Product Portfolio: Cyramza

Table 36 Product Portfolio: Erbitux

Table 37 Cyramza Sales Forecast Through 2022

Table 38 Erbitux Sales Forecast Through 2022

Table 39 Eli Lilly Catalysts and Event Calendar

Table 40 Product Portfolio: Keytruda

Table 41 Keytruda Sales Forecast Through 2022

Table 42 Merck Pipeline View

Table 43 Merck Catalysts and Event Calendar

Table 44 Product Portfolio: Avastin

Table 45 Product Portfolio: Xeloda

Table 46 Avastin Sales Forecast Through 2022

Table 47 Xeloda Sales Forecast Through 2022

Table 48 Roche Pipeline View

Table 49 Roche Catalysts and Event Calendar

Table 50 Product Portfolio: Zaltrap

Table 51 Product Portfolio: Eloxatin

Table 52 Zaltrap Sales Forecast Through 2022

Table 53 Eloxatin Sales Forecast Through 2022

Table 54 LIST OF FIGURES

Fig. 1 Market research process

Fig. 2 Information procurement

Fig. 3 Primary research pattern

Fig. 4 Market research approaches

Fig. 5 Value chain based sizing & forecasting

Fig. 6 QFD modelling for market share assessment

Fig. 7 Stages of colorectal cancer

Fig. 8 Current prevalence across seven major markets - 2016

Fig. 9 Current incidence across seven major markets - 2016

Fig. 10 Geographic sales performance by seven major markets 2016

Fig. 11 Colorectal cancer drugs market by drug class

Fig. 12 Colorectal cancer drugs market share by company 2016 - 2022

Fig. 13 Market trends & outlook

Fig. 14 Market driver relevance analysis (Current & future impact)

Fig. 15 Market restraint relevance analysis (Current & future impact)

Fig. 16 SWOT analysis (Colorectal cancer drugs market)

Fig. 17 SWOT analysis (Amgen)

Fig. 18 SWOT analysis (Bayer)

Fig. 19 SWOT analysis (Bristol Myers Squibb)

Fig. 20 SWOT analysis (Eli Lilly)

Fig. 21 SWOT analysis (Merck)

Fig. 22 SWOT analysis (Roche)

Fig. 23 SWOT analysis (Sanofi)

I would like to order

Product name: Colorectal Cancer (CRC) Drugs/ Therapeutic Market Size, Share & Trends Analysis Report by Drug Class (Chemotherapy, Immunotherapy), By Country (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022

Product link: <https://marketpublishers.com/r/C5C7D5EB705EN.html>

Price: US\$ 5,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C5C7D5EB705EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970